The board of directors of Sino Biopharmaceutical Limited announced that, "Colistimethate Sodium for Injection" (Brand name: Tianyun), an anti-infective drug developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the PRC. The product was filed as a Chemicals Category 3 drug and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, being the first generic drug of its kind that has been approved for marketing in the PRC. The approved indications of Colistimethate Sodium for Injection developed by the Group include: the treatment of acute or chronic infections caused by susceptible strains of sensitive Gram-negative bacilli, especially those caused by susceptible strains of Pseudomonas aeruginosa and Acinetobacter baumannii; it can also be used for the initial treatment of serious infections suspected to be caused by Gram- negative bacteria and the treatment of infections caused by sensitive Gram-negative bacilli. In addition, the active pharmaceutical ingredient ("API") of Colistimethate Sodium is self-produced by the Group, which has obtained the Certification of Suitability to the Monographs of the European Pharmacopoeia ("CEP") issued by the European Directorate for the Quality of Medicines and HealthCare ("EDQM"), and has been successively sold to Spain and other European countries. The CEP is one of the quality certifications for APIs with the highest standard in the world. Obtaining this certification indicates that the processing technology for manufacturing the relevant API has reached the international advanced standard. The approval of the Colistimethate Sodium product for marketing in the PRC will help the Group accelerate the pace of internationalization and facilitate its deployment in overseas markets.